CNC vs PLSE: fair value comparison
Centene Corporation and Pulse Biosciences, Inc. · Updated 2026-10-19
PLSE has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, CNC currently ranks higher by quality score.
| CNC | PLSE | |
|---|---|---|
| Verdict | Overvalued | No estimate yet |
| Last price | $65.36 | $44.43 |
| 12-month range | $31.80–$70.51 | $12.66–$55.20 |
| Rank by discount to fair value | #106 of 108 Healthcare | — |
| Rank by quality score | #205 of 301 Healthcare | #207 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | Moderate | Low |
| Margin trend | Expanding | Expanding |
| Revenue growth | Modest | — |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | — | Mixed |
| 52-week position | The top quarter | The upper-middle quarter |
Full single-stock breakdowns: CNC fair value analysis · PLSE fair value analysis